Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cybin Inc. filings document the U.S. disclosure record for its Helus Pharma clinical-stage pharmaceutical business. Form 6-K reports furnished by the Canadian issuer attach company news releases and, when specified, incorporate exhibits by reference into Form F-10 shelf registration materials.
The filings cover the company’s novel serotonergic agonist pipeline, including HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder, as well as clinical-research collaborations, regulatory-policy statements, scientific advisory board changes, management appointments, chief executive transition disclosures, listing and operating-name updates, and capital-structure matters related to shelf and equity distribution activity.